menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Experts on Call: Connecting Specialists and PCPs to Improve Patient-Centered Obesity Management 

1.00 credits
60 Minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary care setting.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Donna H. Ryan, MD
    Professor Emerita
    Pennington Biomedical Research Center
    Baton Rouge, Louisiana

    Donna Ryan, MD: advisor: Altimmune, Amgen, Biohaven, Boeringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Xeno, YSOPIA, Zealand; speaker: IFA Celtic, Novo Nordisk, Lilly; individual publicly traded stock/stock options: Epitomee, Calibrate, Ro, Scientific Intake, Xeno; clinical trial: Novo Nordisk; data safety monitoring board: IQVIA (Rhythm), Lilly.

    Christopher D. Still, DO, FACN, FACP, FTOS
    Professor of Medicine
    Department of Clinical Sciences
    Geisinger Commonwealth School of Medicine
    Medical Director, Center for Nutrition & Weight Management
    Director, Geisinger Obesity Institute
    Geisinger Health System
    Danville, Pennsylvania

    Christopher D. Still, DO, FACN, FACP: consultant/advisor/speaker: Novo Nordisk, Twenty30 Heath; researcher: Ethicon Endosurgery.
    Program Director
    Robert Kushner, MD, MS
    Professor
    Departments of Medicine and Medical Education
    Northwestern University
    Feinberg School of Medicine
    Director
    Center for Lifestyle Medicine
    Northwestern Medicine
    Chicago, Illinois

    Robert Kushner, MD, MS, FACP, DABOM: consultant/advisor/speaker: Lilly, Novo Nordisk, Pfizer, WW; researcher: Epitomee.
    The planners and content peer reviewers from Clinical Care Options, LLC and RealCME do not have any relevant financial relationships to disclose, except Amy Butts, PA-C, as noted below.

    Amy Butts, PA-C: consultant: Bayer, Novo Nordisk, Provention Bio, Xeris.

  • Target Audience

    Primary target audience for this education are primary care physicians. The secondary target audience is primary care nurse practitioners and physician associates/physician assistants.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Develop strategies to overcome biases and barriers associated with the chronic management of obesity
    • Compare the latest efficacy and safety data of current and emerging antiobesity medications
    • Incorporate guideline recommendations, the latest clinical evidence, and patient-specific factors to select antiobesity medications for long-term management among appropriate patients
    • Apply strategies to improve the likelihood of long-term weight loss based on an assessment of treatment response, patient preferences, and adherence
  • Accreditation and Credit Designation Statements

    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

    Physician Assistant/Physician Associate Continuing Medical Education

    Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 4, 2024. PAs should only claim credit commensurate with the extent of their participation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

     

    Provided by Clinical Care Options, LLC.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • Goal Statement

    The goal of this program is to improve primary care knowledge, competence (application of knowledge), and demonstrated improvement in clinical performance to optimize treatment for patients with obesity.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary care setting.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Donna H. Ryan, MD
    Professor Emerita
    Pennington Biomedical Research Center
    Baton Rouge, Louisiana

    Donna Ryan, MD: advisor: Altimmune, Amgen, Biohaven, Boeringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Xeno, YSOPIA, Zealand; speaker: IFA Celtic, Novo Nordisk, Lilly; individual publicly traded stock/stock options: Epitomee, Calibrate, Ro, Scientific Intake, Xeno; clinical trial: Novo Nordisk; data safety monitoring board: IQVIA (Rhythm), Lilly.

    Christopher D. Still, DO, FACN, FACP, FTOS
    Professor of Medicine
    Department of Clinical Sciences
    Geisinger Commonwealth School of Medicine
    Medical Director, Center for Nutrition & Weight Management
    Director, Geisinger Obesity Institute
    Geisinger Health System
    Danville, Pennsylvania

    Christopher D. Still, DO, FACN, FACP: consultant/advisor/speaker: Novo Nordisk, Twenty30 Heath; researcher: Ethicon Endosurgery.
    Program Director
    Robert Kushner, MD, MS
    Professor
    Departments of Medicine and Medical Education
    Northwestern University
    Feinberg School of Medicine
    Director
    Center for Lifestyle Medicine
    Northwestern Medicine
    Chicago, Illinois

    Robert Kushner, MD, MS, FACP, DABOM: consultant/advisor/speaker: Lilly, Novo Nordisk, Pfizer, WW; researcher: Epitomee.
    The planners and content peer reviewers from Clinical Care Options, LLC and RealCME do not have any relevant financial relationships to disclose, except Amy Butts, PA-C, as noted below.

    Amy Butts, PA-C: consultant: Bayer, Novo Nordisk, Provention Bio, Xeris.

  • Target Audience

    Primary target audience for this education are primary care physicians. The secondary target audience is primary care nurse practitioners and physician associates/physician assistants.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Develop strategies to overcome biases and barriers associated with the chronic management of obesity
    • Compare the latest efficacy and safety data of current and emerging antiobesity medications
    • Incorporate guideline recommendations, the latest clinical evidence, and patient-specific factors to select antiobesity medications for long-term management among appropriate patients
    • Apply strategies to improve the likelihood of long-term weight loss based on an assessment of treatment response, patient preferences, and adherence
  • Accreditation and Credit Designation Statements

    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

    Physician Assistant/Physician Associate Continuing Medical Education

    Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 4, 2024. PAs should only claim credit commensurate with the extent of their participation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

     

    Provided by Clinical Care Options, LLC.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • Goal Statement

    The goal of this program is to improve primary care knowledge, competence (application of knowledge), and demonstrated improvement in clinical performance to optimize treatment for patients with obesity.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule30 May 2024